{"nctId":"NCT02091414","briefTitle":"A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.","startDateStruct":{"date":"2006-08"},"conditions":["Heart Transplantation"],"count":36,"armGroups":[{"label":"MMF, CsA, Corticosteroids","type":"EXPERIMENTAL","interventionNames":["Drug: mycophenolate mofetil (MMF)","Drug: cyclosporine A (CsA)","Drug: corticosteroids"]}],"interventions":[{"name":"mycophenolate mofetil (MMF)","otherNames":["CellCept"]},{"name":"cyclosporine A (CsA)","otherNames":[]},{"name":"corticosteroids","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* patients receiving their first heart transplant (single organ transplant).\n\nExclusion Criteria:\n\n* patients with a positive donor-specific cross-match at the time of transplantation;\n* patients with any antibody-treated acute rejection;\n* known contraindications to treatment with sirolimus;\n* history of malignancy, other than excised non-melanoma skin cancer which has not recurred for 2 years.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week","description":"Percentage of participants with BPAR of greater than or equal to (â‰¥) International Society of Heart and Lung Transplant (ISHLT) Grade III. The ISHLT graded symptoms on a scale of Grade 0 through VI. Grade 0 equals (=) no rejection. Grade IA = regional (perivascular or interstitial) infiltration and no necrosis, and grade IB = dissemination but little infiltration and no necrosis. Grade II = 1 focus of invasive infiltration with or without (+/-) associated cardiomyocyte necrosis. Grade IIIA = 2 or more foci of invasive infiltration +/- associated cardiomyocyte necrosis, and grade IIIB = diffuse inflammatory pathological changes associated with cardiomyocyte necrosis. Grade IV = diffuse, infiltrative multi-foci +/- edema; +/- hemorrhage; and +/-vasculitis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Graft Loss Within 24 Weeks of Transplantation","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Use of Additional Immunosuppressants Not Specified in the Protocol Within 24 Weeks of Transplantation","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Discontinuing Immunosuppressants (MMF) for More Than 14 Consecutive Days or 30 Cumulative Days Within 24 Weeks of Transplantation","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Lost To Follow Up Within 24 Weeks of Transplantation","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Normal Serum Creatinine and Blood Urea Nitrogen (BUN) Values At Baseline (BL) And During Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Normal Serum Creatinine and BUN Values at Baseline and Abnormal Values During Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and Normal Values During Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and During Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.22","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":36},"commonTop":["Cough","Elevated blood sugar","Hyperglycemia","Tachycardia","Hypertension"]}}}